Cerevel Therapeutics Investor Relations Material
Latest events
Q3 2023
Cerevel Therapeutics
Q1 2024
8 May, 2024
Q4 2023
27 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cerevel Therapeutics Holdings Inc
Access all reports
Cerevel Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company specializes in targeting brain receptor systems to address conditions such as Parkinson’s disease, schizophrenia, and epilepsy. Cerevel Therapeutics Holdings Inc. is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CERE
Country
🇺🇸 United States